The Latest on Gene Silencing Biotech Firm Arrowhead Pharmaceuticals Fiscal Year 2019 Results

By John Heerdink LinkedIn

Recently, Arrowhead Pharmaceuticals (ARWR), a company that develops medicines that treat intractable diseases by silencing genes that cause them, announced its earnings report for the quarter ending September 30, 2019. The company hosted a live webcast of the event, a replay of which will be available on the company’s website for 90 days. To access the audio replay, interested parties can dial in 855-859-2056 or 404-537-3406 with Conference ID 7768049.

Some recent developments:

  • Janssen Pharmaceuticals, Inc., the Arrowhead collaborator and part of the Janssen Pharmaceutical Companies of Johnson & Johnson, treated patients with a Phase 2b triple combination study called REEF-1, equipped to serve 450 patients with chronic hepatitis B infection generating Arrowhead with a $25 million milestone payment.
  • Arrowhead presented new clinical research on two cardiometabolic candidates, ARO-APOC3 used for the treatment for patients with severe hypertriglyceridemia and familial chylomicronemia syndrome, and ARO-ANG3 used for the treatment of dyslipidemias, such as homozygous familial hypercholesterolemia (HoFH), and metabolic diseases, at the American Heart Association Scientific Sessions 2019.
  • Discussed Arrowhead’s emerging pipeline of RNAi therapeutics and advancements being made to the company’s proprietary Targeted RNAi Molecule (TRIMTM) platform.

Shares of ARWR closed at $73.01/share, +5.78%. The 52-week range is $10.41-$73.72.

Also, check out Neubase Therapeutics (NBSE) whose gene silencing platform is beginning to draw a great deal of attention.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

nov2(13)

(Read Original Story: Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results in Business Wire)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us